Revenue
No reported data
Apogee Therapeutics, Inc. (APGE)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $214.7M | $167.9M | $68.4M | $27.8M |
| Operating expenses | $285.6M | $216.9M | $93.0M | $30.7M |
| Operating income | −$285.6M | −$216.9M | −$93.0M | −$30.7M |
| Net income | −$255.8M | −$182.1M | −$84.0M | −$39.8M |
| Basic EPSper diluted share | -$4.22 | -$3.30 | -$3.36 | -$16.16 |
| Diluted EPSper diluted share | -$4.22 | -$3.30 | -$3.36 | -$16.16 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Dambkowski CarlChief Medical Officer | SellCommon Stock | 26.4K | $132.60 | $3.50M | 179.2K |
| Jun 22, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASChief Executive Officer | SellCommon Stock | 80.0K | $132.54 | $10.60M | 1.02M |
| Jun 10, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASChief Executive Officer | SellCommon Stock | 614 | $86.89 | $53.4K | 1.10M |
| Jun 10, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASChief Executive Officer | SellCommon Stock | 2.3K | $86.27 | $198.9K | 1.10M |
| Jun 10, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASChief Executive Officer | SellCommon Stock | 1.6K | $85.19 | $134.3K | 1.10M |